Association between the extent of intrapulmonary spread on chest CT and false-negative results of T-SPOT.TB in pulmonary tuberculosis: a retrospective study

胸部CT肺内扩散程度与肺结核T-SPOT.TB假阴性结果之间的关联:一项回顾性研究

阅读:2

Abstract

BACKGROUND: The T-SPOT.TB assay is widely used for the adjunctive diagnosis of tuberculosis (TB). However, clinicians often encounter false-negative T-SPOT.TB results. The extent of TB spread may influence host immune functions, which can influence the results of the T-SPOT.TB test. However, few previous reports have investigated the association between radiologic pulmonary tuberculosis (PTB) severity and T-SPOT.TB test results. METHODS: We retrospectively investigated patients with culture-confirmed pulmonary TB (PTB) at the Jikei University Daisan Hospital between September 2016 and December 2021. We aimed to clarify the association of PTB severity, according to computed tomography (CT), with the false-negative results of the T-SPOT.TB test. RESULTS: Among 193 patients with PTB, 43 (22.3%) had false-negative T-SPOT.TB results. High rates of false-negative results were noted for 7/18 (38.9%) patients with PTB spread in two lung segments (mild PTB) and 16/39 (41.0%) patients with PTB spread in 19 lung segments (severe PTB). Multivariate logistic regression analysis showed that mild or severe PTB (odds ratio [OR]: 3.23; 95% confidence interval [CI]: 1.46-7.13; P = 0.004) and lymphopenia (OR: 3.33; 95% CI: 1.20-9.26; P = 0.02) were statistically significant risk factors for false-negative results. CONCLUSIONS: Mild or severe intrapulmonary lesions on chest CT might be associated with the false-negative results of the T-SPOT.TB assay. Additionally, estimating the intrapulmonary spread of PTB using chest CT could serve as a useful supplementary tool in diagnosing patients with PTB who receive false-negative results on the T-SPOT.TB test.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。